Quote | Annexon Inc. (NASDAQ:ANNX)
Last: | $6.235 |
---|---|
Change Percent: | 2.38% |
Open: | $6.12 |
Close: | $6.09 |
High: | $6.42 |
Low: | $6.05 |
Volume: | 839,019 |
Last Trade Date Time: | 07/25/2024 03:00:00 am |
News | Annexon Inc. (NASDAQ:ANNX)
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE N...
2024-06-26 07:40:05 ET More on Annexon Biosciences Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place Annexon: Unforced Error Sullies Prospects Biggest stock movers today: BBWI, GME, HQY, and more Annexon spikes as lead asset h...
Message Board Posts | Annexon Inc. (NASDAQ:ANNX)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE N...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First Targeted Therapy Approved for the Treatment of GBS BRISBANE, Calif., June 18, 2024 (GLOBE...